TheranosticTrials.org

Clinical Trial · NCT06091748

Gallium (68Ga) Edotreotide PET/CT for Imaging Patients With Gastrointestinal Pancreatic Neuroendocrine Tumors

Overview

This is a single-arm imaging study using DOTATOC peptide, labelled with the Gallium (68Ga) tracer.

Sponsor

Jiangsu HengRui Medicine Co., Ltd.

Phase

Phase 3

ClinicalTrials.gov

NCT06091748

Drug / Compound

DOTATOC

Isotope(s):
Target(s):
  • SSTR2
Ligand Class: Peptides
Chelator: DOTA

Eligibility

Inclusion

  • ECOG performance status 0 or 1;
  • Confirmed or suspicion of GEP-NET.

Exclusion

  • Individuals with concurrent active infections or with unexplained fever \>38.5°C for more than 1 hour during the screening period or prior to administration of investigational medication.
  • Individuals planning to be pregnant, and lactating women;
  • Unable to lie flat for the entire imaging duration (e.g. persistent cough, claustrophobia, severe arthritis, etc.), unable to enter the PET/CT device;